Skip to main content

Table 2 HR (95% CI) for risk of myocardial infarction according to quartiles of the TyG index

From: Triglyceride–glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort

Variables

Quartiles of the TyG index

Per 1 unit increase

P for trend

Q1

Q2

Q3

Q4

Baseline TyG index

Case, n (%)

220 (0.89)

315 (1.27)

430 (1.74)

590 (2.39)

  

Incidence rate, per 1000 person-y

0.84 (0.74–0.96)

1.21 (1.08–1.35)

1.65 (1.51–1.82)

2.28 (2.11–2.48)

  

Model 1

Reference

1.39 (1.17–1.65)

1.88 (1.60–2.21)

2.69 (2.30–3.14)

1.61 (1.51–1.72)

 < 0.0001

Model 2

Reference

1.33 (1.12–1.58)

1.73 (1.47–2.05)

2.41 (2.06–2.83)

1.54 (1.43–1.65)

 < 0.0001

Model 3

Reference

1.26 (1.06–1.50)

1.60 (1.36–1.89)

2.08 (1.77–2.45)

1.43 (1.33–1.53)

 < 0.0001

Sensitivity analysisa

Reference

1.24 (1.01–1.51)

1.62 (1.34–1.96)

2.02 (1.67–2.44)

1.39 (1.28–1.52)

 < 0.0001

Sensitivity analysisb

Reference

1.22 (1.02–1.46)

1.50 (1.24–1.82)

3.60 (1.48–8.80)

1.63 (1.32–2.02)

 < 0.0001

Updated mean TyG index

Case, n (%)

264 (1.07)

318 (1.29)

421 (1.70)

552 (2.23)

  

Incidence rate, per 1000 person-y

1.02 (0.90–1.15)

1.22 (1.09–1.36)

1.61 (1.46–1.36)

2.13 (1.96–2.32)

  

Model 1

Reference

1.20 (1.00–1.43)

1.54 (1.24–1.94)

2.10 (1.57–2.79)

1.74 (1.48–2.04)

 < 0.0001

Model 2

Reference

1.13 (0.95–1.36)

1.42 (1.14–1.78)

1.86 (1.39–2.49)

1.64 (1.39–1.93)

 < 0.0001

Model 3

Reference

1.07 (0.90–1.29)

1.30 (1.03–1.62)

1.58 (1.18–2.12)

1.49 (1.26–1.76)

 < 0.0001

Sensitivity analysisa

Reference

1.01 (0.78–1.20)

1.24(1.02–1.58)

1.42 (1.13–2.05)

1.47 (1.32–1.63)

 < 0.0001

Sensitivity analysisb

Reference

1.17 (0.86–1.59)

1.21 (0.90–1.64)

1.80 (1.36–2.38)

1.86 (1.25–2.57)

 < 0.0001

  1. CI confidence interval, HR hazard ratio, TyG triglyceride glucose
  2. Model 1, adjusted for age and sex at baseline
  3. Model 2, adjusted for variables in model 1 plus level of education, income, smoking, alcohol abuse, physical activity, and BMI at baseline
  4. Model 3, adjusted for variables in model 2 plus SBP, DBP, a history of hypertension, diabetes mellitus, and dyslipidemia, antidiabetic drugs, lipid-lowering drugs, antihypertensive drugs, HDL-C, LDL-C, and hs-CRP at baseline
  5. aSensitivity analysis was adjusted for variables in model 3 and further excluded all deaths during the follow-up visits
  6. bSensitivity analysis was excluded those with abnormal FBG (≥ 7.0 mmol/L) or abnormal TG level (≥ 1.7 mmol/L) at baseline, and adjusted for covariates in Model 3
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840